The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 22, 2022
Filed:
Jun. 20, 2019
Applicant:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Inventor:
Alison Crawford, Dobbs Ferry, NY (US);
Assignee:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); A61P 35/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/3092 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01);
Abstract
The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., ovarian cancer or pancreatic cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specifically binds Mucin 16 (MUC16) and CD3.